TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Nottingham Extended Activities of Daily Living (NEADL)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Maximum Tolerated Dose (MTD) of CCI-779 and Bryostatin-1
Endpoint domain: Adverse events/effects
Primary endpoint: Sensibility of saliva samples for detection of SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Composition of microorganisms in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biomarkers of inflammation in intestines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants who Attend More than Half of Scheduled Sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Client Satisfaction Questionnaire (CSQ-8) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Surface healed skin (cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Absence of tumorigenicity at injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Duration in Days of Grade 4 Neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Modification of therapeutical decision
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: treatment efficacy of NB-UVB phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects That Are Lice-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Allergenic food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of pulse oximeter device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of milk protein-bound amino acid labels in blood protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain alleviation measured by Numerical Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Catheter-related bladder discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or cardiovascular events within 30 days after revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Ipsilateral stroke or death beyond 30 days to 12 months after revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Capability of Performing EUS-FNTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: FAOS - PAIN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment Exposure Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of correct answers
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fall incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to claudication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beck Depression Index II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COPE Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: State-Trait Anxiety Inventory form Y1 and Y2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral Avoidance/Inhibition Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bowel Health Questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and Toxicity of Treatment Regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects receiving RBC transfusion or Hb < 8.0 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CPAP Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EIBI Bleeding Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Best-corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Goal attainment scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vineland Adaptive Behavior Scale
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Multiple choice test on cardiovascular disease
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: IBS symptom severity scale (IBS-SSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of GBT440 in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUCt) of GBT440 in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 extrapolated to infinity (AUCinf) of GBT440 in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-thawing survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in Visual Acuity at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Acuity at Month 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specimen Adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual characteristics on CLE-imaging and pOCT imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virological Response 12 Weeks After End of Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cost of Care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum observed serum Genakumab concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum Genakumab concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the serum IL-1β for pharmacodynamics study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for Photocoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Recurrence of Herpes Labialis Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of Herpes Labialis Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fraction dd-cfDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 h ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic performance (sensitivity and specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of lymphatic Filariasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence on Onchocerciasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Log(ENA-Period 2 End/ENA Period 1 End)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Half Emptying Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of High-Grade Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary EGF Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary EGF Protein Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of total sleep time of polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change of sleep latency of polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change of sleep efficiency of polysomnography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Number of Smokers at the Time of the Interview
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Current and Former Smokers Who Smoked Cigarettes at the Time of Their Cancer Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Cancer Diagnosis to the Date of the Interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in UPDRS part-III (Motor examination) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in Autonomic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Inflammatory Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Heart Rate Variability (HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychophysiological Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Reports and Observations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRI Brain-Mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Language Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in Aphasia Quotient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Living with Aphasia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death after intensive care
Endpoint domain: Mortality/survival
Primary endpoint: Readmission after intensive care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of ANC <1.0 x 103/μl (Grade 3-4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to recovery of ANC level ≥1.5 x 103/μl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hepatic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: CMV IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral load PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti-CML Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCS scores ranking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: RAPID-3 scores ranking
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Walking Capacity-Self-selected walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Capacity-Fast walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking Capacity-Endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicle maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: rate of recurrence of acute diverticulitis requiring hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: change of lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement of fertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients with viral load < 50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: memory preservation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: pulmonary inflammatory mediator reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Brain auditory evoked response (BAER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Recovery 40 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Aripiprazole concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paliperidone concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Olanzapine concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quetiapine concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risperidone concentration in venous and capillary plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in GLP-1 and GIP postprandial secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Spasticity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: average changes in patients' systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent of patients who maintain BP control, among those with controlled baseline BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire (FIQ) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Amplitude Glycemic Excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: death related to exacerbations
Endpoint domain: Mortality/survival
Primary endpoint: Urinary 6-sulfatoxy-melatonin (U6SM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pancreatic islet beta-cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid scan findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ST shift correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of oral topotecan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Medication Adherence Completion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weekly Average of Daily Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistent rate of atrial fibrillation diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight Loss of 5% or More
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complications after the operation
Endpoint domain: Adverse events/effects
Primary endpoint: Pain during pulpotomy score on Faces Pain Scale-Revised
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during pulpotomy score on Sound Eye Motor scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean home systolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Takotsubo
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence of Takotsubo
Endpoint domain: Mortality/survival
Primary endpoint: Patient's prospective health status following Takotsubo event
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Tumor Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: skin conductance response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: number of mediastinoscopy avoided
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 28-day all cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients showing a positive response to sacral nerve stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of infestation and prevalence of lice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pharmacokinetics of rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of rivaroxaban
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients correctly diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control level of Asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart Rate Monitor Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Low Disease Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to sputum culture conversion from positive to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DNA methylation pattern in adipose tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Putative novel candidate genes underlying obesity phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RNA sequencing analysis in adipose tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of 18F-FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Memory Control Advantage Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Induction of laxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in atherosclerotic plaque burden (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency of attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects found with one or more of 96 ctDNA mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of copies of mutant alleles found in the positive subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of ctDNA found within the total amount of circulating free DNA (cfDNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Visual Analogue Scales
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Achieved Platelet Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Periodontal disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax: Maximum Observed Serum Urate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-t): Area Under the Serum Concentration-time Curve From Time 0 to Time t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax: Time of Maximum Serum Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (CR, CRi, PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fissure healing at 1 month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days to pain-free defecation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness in stopping seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Engraftment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Neutrophil Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Platelet Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3-4 Acute Graft-versus-host Disease
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Persistence Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Relapse of Malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Severity of Stress Urinary Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes